GlassScriptPhysician profile
Christopher L Kiker
NPI 1679908057
$7,785.34
in general payments reported to CMS, 2019-2025
43 companies · $1,631 in 2025
The $1,631 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.31 · 2020: $339 · 2021: $926 · 2022: $1,592 · 2023: $1,674 · 2024: $1,545 · 2025: $1,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,850.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,199.96 | 2021-2025 | |
| Lilly USA, LLC | $973.84 | 2020-2025 | Mounjaro, Jardiance, Trulicity |
| Otsuka America Pharmaceutical, INC. | $798.04 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Astrazeneca Pharmaceuticals LP | $599.83 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $537.11 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $444.97 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.37 | 2020-2025 | Jardiance |
| Glaxosmithkline, LLC. | $310.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Sanofi-Aventis U.S. LLC | $309.73 | 2020-2023 | |
| Amgen INC. | $303.64 | 2019-2025 | Otezla, Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $269.10 | 2020-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $228.10 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.39 | 2023-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $135.58 | 2020-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $121.10 | 2022-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kiker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.